<DOC>
	<DOCNO>NCT01803152</DOCNO>
	<brief_summary>The use adjuvant vaccination autologous dendritic cell ( DC ) mature situ load tumor lysates derive autologous refractory sarcoma tissue safe , feasible potentially beneficial patient diagnose sarcoma . This vaccination result evidence immune stimulation tumor antigen . In addition , combine myeloid derive supressor cell ( MDSC ) inhibition use gemcitabine DC vaccination method safe feasible show improve immune parameter DC vaccination without MDSC inhibition .</brief_summary>
	<brief_title>Dendritic Cell Vaccine With Without Gemcitabine Pre-Treatment Adults Children With Sarcoma</brief_title>
	<detailed_description>This dose find / dose escalation study dendritic cell ( DC ) vaccination administer imiquimod ( Aldara® ) treat skin refractory sarcoma patient , include subsequent cohort subject receive DC gemcitabine ( Gemzar® ) therapy . There three intend dose level cell number DC per treatment - 3 , 6 12 million cell per treatment . There 5 subject accrue per dose level . If one subject first 5 patient per dose level experience dose limit toxicity ( DLT ) , dose level expand 8 subject . If 2 subject give dose level experience DLT , maximum tolerate dose ( MTD ) consider exceed . The MTD cell dose level le 1 5 less 2 8 subject experience DLT . Provision make de-escalate dose level 0 , 1.5 million cell per treatment , dose level 1 toxic . This 5+3 design modify conventional 3+3 dose escalation schema use test cytotoxic agent Phase I trials . A low rate DLTs therefore potentially accept study conventional dose escalation trial cytotoxic agent . If MTD reach , consider third dose level recommend phase 2 dose ( RP2D ) go forward expand dose level 8 subject total . After MTD/RP2D reach , commence addition gemcitabine pre-treatment study therapy cell dose hold dose determined DC alone . This include weekly gemcitabine infusion three week four initiation vaccination . Gemcitabine treatment commence soon subject safely recovered pheresis , within 2 week completion pheresis . DC vaccination begin two week third administration gemcitabine . Gemcitabine dose constant , combination gemcitabine MTD/RP2D DC alone prove toxic , de-escalate dose DC gemcitabine containing level . This de-escalation mirror dose escalation DC alone , MTD DC plus gemcitabine define dose level le 1 5 less 2 8 subject experience DLT . Subjects undergo resection tumor follow pheresis acquire monocyte separate used grow DC . Subjects undergoing gemcitabine therapy begin vaccination approximately two week pheresis , depend manufacture time DC . All subject undergo lysate boost administration .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Age : 1 100 year old . 2 . Histologically cytologically confirm sarcoma either relapse without know curative therapy . Both bone sarcoma soft tissue sarcoma eligible . Osteosarcoma , chondrosarcoma , Ewing 's sarcoma diagnose sarcoma eligible long soft tissue excise use prepare lysate . Subjects present lesion comprise bone exclude . Any number prior therapy allow , include zero . 3 . No radiotherapy sit plan and/or chemotherapy plan study period . No radiotherapy chemotherapy receive least 4 week first vaccine administration . To allow well local control without introduce undue toxicity trial , brachytherapy time surgery schedule end one week first vaccination allow radioactive source remove ( e.g . catheter place removable implanted seed allow ) . In event positive margin determine surgical resection , determine time placement brachytherapy catheter , external beam radiotherapy may start last DC vaccination administer lysate boost begin , radiation must plan complete first lysate boost . 4 . No treatment corticosteroid , antihistamine salicylate least 1 week first vaccination . 5 . Adequate organ function ( measure enrollment ) Absolute neutrophil count ( ANC ) ≥ 750/L Lymphocytes ≥ 500/L Platelets ≥ 75,000/L Hemoglobin ≥ 9 g/dL Aspartate aminotransferase ( AST ) /Alanine transaminase ( ALT ) ≤ 2.5 X upper limit normal ( ULN ) ; liver metastasis , ≤ 5 X ULN Serum Creatinine ≤ 1.5 X ULN Total Bilirubin ≤ 3 X ULN Albumin &gt; 2 g/dL 6 . Karnofsky/Lansky score ≥ 70 % Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 7 . Subjects must agree use adequate method contraception abstinence throughout 4 week study treatment completion . 8 . Life expectancy &gt; 3 month . 9 . Written consent patient parent ( ) ( patient &lt; 18 year ) institutional review board ( IRB ) approve informed consent form prior studyspecific evaluation . Assent required child per University Miami ( UM ) IRB guideline . Subject must capable understanding investigational nature , potential risk benefit study able provide valid inform consent . 1 . Pregnancy 2 . Breast feeding female . 3 . Any concomitant participation therapeutic trial 4 . Virus serology know positive HIV ( test require absence clinical suspicion ) 5 . Documented immunodeficiency autoimmune disease 6 . Concomitant treatment corticosteroid , antihistamine ( H1 H2 inhibitor ) salicylate . Patients may eligible treatment stop least 1 week first vaccination . 7 . Brain metastasis unless stable 3 month treatment direct specifically . 8 . Known allergy gemcitabine formulation component . Intolerant gemcitabine Does apply cohort treat without gemcitabine Prior therapy gemcitabine allow cohort 9 . Refusal use adequate contraception fertile patient ( female male ) study 30 day last dose study treatment . 10 . Any serious uncontrolled medical psychiatric condition opinion investigator make patient able participate study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Sarcoma</keyword>
	<keyword>Relapsed Sarcoma</keyword>
	<keyword>Dendritic Cell</keyword>
	<keyword>Myeloid Derived Suppressor Cells</keyword>
	<keyword>MDSC</keyword>
	<keyword>MDSC Inhibition</keyword>
</DOC>